Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is (a) male or (b) female and not of reproductive potential, or (c) female of reproductive potential has a serum beta-hCG level consistent with the nongravid state at screening and agrees to use acceptable contraception;~* Current primary diagnosis of recurrent major depressive disorder, without psychotic features, with a current moderate or severe depressive episode;~* Duration of the current major depressive episode must be at least 2 months but no more than 18 months at Screening;~* Participant has undergone an adequate trial of an antidepressant (one of identified SSRIs or SNRIs, or bupropion) for the current depressive episode.~Key Exclusion Criteria:~* Current primary psychiatric diagnosis other than major depression;~* Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or other psychotic disorder;~* Alcohol or other substance abuse or dependence (excluding nicotine);~* Clinically significant abnormality or disease of the central nervous system (including dementia and other cognitive disorders or traumatic brain injury);~* Imminent risk of self-harm or of harm to others;~* Participant is a psychiatric inpatient;~* Participant has been on continuous antidepressant treatment for \>18 months prior to Screening visit;~* Inadequate response to more than 3 adequate antidepressant trials (including the current antidepressant treatment trial) for treatment of the current depressive episode;~* Participant ever received electroconvulsive therapy, transcranial magnetic stimulation, or vagal nerve stimulation for treatment of depression;~* History of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep-related breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive daytime sleepiness or difficulty sleeping due to a medical condition;~* Clinical, laboratory, or electrocardiogram (ECG) evidence of significant systemic disease;~* Cardiovascular event (e.g., myocardial infarction) or procedure (e.g., coronary artery bypass surgery) within 3 months of study;~* History of malignancy ≤5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer;~* Body Mass Index \>40 kg/m\^2;~* Pregnancy, breast-feeding, or expecting to become pregnant.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Filorexant 10 mg (Treatment Phase) (Type: EXPERIMENTAL): Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
- Placebo (Treatment Phase) (Type: PLACEBO_COMPARATOR): Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
- Filorexant 10 mg/Filorexant 10 mg (Run-out Phase) (Type: EXPERIMENTAL): Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
- Filorexant 10 mg/Placebo (Run-out Phase) (Type: PLACEBO_COMPARATOR): Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
- Placebo/Placebo (Run-out Phase) (Type: PLACEBO_COMPARATOR): Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).